Aduro BioTech awarded for tularemia work

The Defense Threat Reduction Agency has awarded Aduro BioTech, a clinical-stage immunotherapy company, with the “Outstanding Scientific Achievement” award for the company’s major progress in developing vaccines for the potential bioterror threat tularemia.

The award was presented to Dr. Justin Skoble, associate director of biodefense and process development at Aduro BioTech, at the 2010 Chemical and Biological Defense Science and Technology Conference in Orlando, Florida.

Aduro BioTech developed its Listeria monocytogenes-based tularemia vaccines as part of the five year, $24.8 million Tularemia Vaccine Development Contract awarded by the National Institute of Allergy and Infectious Diseases.

Tularemia, which is also known as rabbit fever, is caused by the bacterium Francisella tularensis and is a potential bioterrorism threat because of the widespread and serious illness that could occur if the organism becomes aerosolized.

Aduro BioTech has developed two vaccine platforms, including a live-attenuated, double-deleted Lm vaccine platform and a photochemically-killed by metabolically-active vaccine platform. Both vaccine platforms significantly protected rats infected with tularemia.
The results were presented to the conference as an abstract, and were then selected for an oral presentation. The research was awarded the Outstanding Scientific Achievement award out of over 180 oral presentations and 600 poster presentations.

“We are honored to win this award and are excited about the opportunity to with DTRA to further advance the development of a tularemia vaccine,” Skoble said.